<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03870555</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-954-1009</org_study_id>
    <secondary_id>U1111-1224-9803</secondary_id>
    <nct_id>NCT03870555</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, 3-Period, Incomplete Block Design Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-954 in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and PK of single ascending
      intravenous doses of TAK-954.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-954. This study will assess the safety,
      tolerability, PK and PD of single ascending TAK-954 higher intravenous doses than those
      previously studied.

      The study will enroll approximately 6 participants. Participants will be randomly assigned
      (By chance, like flipping a coin) to one of the three treatment sequences—which will remain
      undisclosed to the participant and study doctor during the study (unless there is an urgent
      medical need).

      In each treatment sequence, each participant will receive 2 doses of active drug out of 3
      dose levels (TAK-954 0.5 mg, TAK-954 1 mg, or TAK-954 2 mg) and 1 dose of Placebo. Dose
      escalation will be based on the available safety/tolerability data from the previous period.

      This single center trial will be conducted in the United States. The overall time to
      participate in this study is approximately 73 days. Participants will make a final visit on
      Day 16 after receiving their last dose of study drug for a follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2019</start_date>
  <completion_date type="Actual">May 16, 2019</completion_date>
  <primary_completion_date type="Actual">May 16, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) for TAK-954</measure>
    <time_frame>Dosing on Day 2 in Period 1 up to 14 days after last dose of study drug on Day 2 of Period 3 (up to Day 52)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Vital Signs for TAK-954</measure>
    <time_frame>Dosing on Day 2 in Period 1 up to 14 days after last dose of study drug on Day 2 of Period 3 (up to Day 52)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG) for TAK-954</measure>
    <time_frame>Dosing on Day 2 in Period 1 up to 14 days after last dose of study drug on Day 2 of Period 3 (up to Day 52)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Notable Shifts From Baseline to Abnormal Post-dose in Clinical Laboratory Values for TAK-954</measure>
    <time_frame>Dosing on Day 2 in Period 1 up to 14 days after last dose of study drug on Day 2 of Period 3 (up to Day 52)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954</measure>
    <time_frame>Day 2 pre-dose and at multiple time points (up to 336 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954</measure>
    <time_frame>Day 2 pre-dose and at multiple time points (up to 336 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ceoi: Plasma Concentration Observed at the End of Infusion for TAK-954</measure>
    <time_frame>Day 2 pre-dose and at multiple time points (up to 336 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL: Total Clearance After Intravenous Administration for TAK-954</measure>
    <time_frame>Day 2 pre-dose and at multiple time points (up to 336 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz: Volume of Distribution During the Terminal Disposition Phase After Intravenous Administration for TAK-954</measure>
    <time_frame>Day 2 pre-dose and at multiple time points (up to 336 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ae: Amount of Unchanged Drug Excreted in the Urine for TAK-954 on Day 2 up to 12 Hours Post-dose</measure>
    <time_frame>Day 2 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ae: Amount of Unchanged Drug Excreted in the Urine for TAK-954 on Day 2 up to 24 Hours Post-dose</measure>
    <time_frame>Day 2 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ae: Amount of Unchanged Drug Excreted in the Urine for TAK-954 on Day 2 up to 36 Hours Post-dose</measure>
    <time_frame>Day 2 pre-dose and at multiple time points (up to 36 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fe: Fraction of TAK-954 Excreted in Urine on Day 2 up to 12 Hours Post-dose</measure>
    <time_frame>Day 2 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fe: Fraction of TAK-954 Excreted in Urine on Day 2 up to 24 Hours Post-dose</measure>
    <time_frame>Day 2 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fe: Fraction of TAK-954 Excreted in Urine on Day 2 up to 36 Hours Post-dose</measure>
    <time_frame>Day 2 pre-dose and at multiple time points (up to 36 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLR: Renal Clearance for TAK-954</measure>
    <time_frame>Day 2 pre-dose and at multiple time points (up to 36 hours) post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Stool of TAK-954 Within 36 Hours Post-dose on Day 2</measure>
    <time_frame>Day 2 dosing and at multiple time points (up to 36 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Stools of TAK-954 Within 36 Hours Post-dose on Day 2</measure>
    <time_frame>Day 2 dosing and at multiple time points (up to 36 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instances of Stool Type of TAK-954 Based on Bristol Stool Form Scale</measure>
    <time_frame>Day 2 dosing and at multiple time points (up to 36 hours) post-dose</time_frame>
    <description>Number of occurrences for each stool type was reported based on their type assessed from Bristol Stool form scale. The Bristol Stool Form Scale was used to assess the stool shape using a 7-point scale. Where, Type 1 = separate hard lumps, like nuts (hard to pass), Type 2 = sausage-shaped but lumpy, Type 3 = like a sausage but with cracks on the surface, Type 4 = like a sausage or snake, smooth and soft, Type 5 = soft blobs with clear-cut edges (passed easily), Type 6 = fluffy pieces with ragged edges, a mushy stool, Type 7 = watery, no solid pieces; entirely liquid. A score of 1 or 2 indicates constipation and a score of 6 or 7 indicates diarrhea.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.
Period 2: TAK-954 0.1 milligram (mg), infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg infusion, administered intravenously over 60-minutes, once on Day 2.
Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg infusion, administered intravenously over 60-minutes, once on Day 2.
A washout period of at least 16 days will be maintained between each Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg infusion, administered intravenously over 60-minutes once on Day 2.
Period 2: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.
Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg, infusion, administered intravenously over 60-minutes, once on Day 2.
A washout period of at least 16 days will be maintained between each Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg, infusion, administered intravenously over 60-minutes once on Day 2.
Period 2: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg, infusion, administered intravenously over 60-minutes, once on Day 2.
Period 3: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2. A washout period of at least 16 days will be maintained between each Treatment Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-954</intervention_name>
    <description>TAK-954 infusion administered intravenously.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-954 Placebo</intervention_name>
    <description>TAK-954 placebo-matching infusion intravenous.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Body mass index (BMI) greater than or equal to (&gt;=) 18 and less than or equal to (&lt;=)
             32 kilogram per square meter (kg/m^2), weighing &gt;=50 kilogram (kg) at screening.

          2. Medically healthy with no clinically significant medical history, physical
             examination, laboratory profiles, vital signs, orthostatic vital signs, or ECGs, as
             deemed by the Investigator or designee.

          3. Continuous non-smoker who has not used nicotine-containing products for at least 3
             months prior to the first dose and throughout the study, based on participant
             self-reporting.

        Exclusion Criteria:

          1. History or presence of alcoholism or drug abuse within the past 2 years prior to the
             first dosing.

          2. Has infrequent bowel movements (less than approximately once per day) within 30 days
             prior to first dosing.

          3. Recent history of abnormal bowel movements, such as diarrhea, loose stools, or
             constipation, within 2 weeks of first dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <results_first_submitted>May 5, 2020</results_first_submitted>
  <results_first_submitted_qc>June 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 24, 2020</results_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03870555/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 18, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03870555/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in the United States from 08 March 2019 to 16 May 2019.</recruitment_details>
      <pre_assignment_details>Healthy adult participants were enrolled in this 3-period cross-over study in 1 of the 3 treatment sequences to receive TAK-954 0.1 milligram (mg) or Placebo on Day 1 (Lead-in Dose), followed by TAK-954 (0.5 mg, 1 mg or 2 mg) or Placebo on Day 2 (Treatment Dose) of each study period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1: Placebo + TAK-954 1 mg + TAK-954 2 mg</title>
          <description>Period 1: TAK-954 placebo-matching infusion, intravenously, once on Day 1 and Day 2.
Period 2: TAK-954 0.1 mg, infusion, intravenously, once on Day 1 and TAK-954 1 mg infusion, intravenously, once on Day 2.
Period 3: TAK-954 0.1 mg, infusion, intravenously, once on Day 1 and TAK-954 2 mg infusion, intravenously, once on Day 2.
A washout period of at least 16 days was maintained between each Treatment Period.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2: TAK-954 0.5 mg + Placebo + TAK-954 2 mg</title>
          <description>Period 1: TAK-954 0.1 mg, infusion, intravenously, once on Day 1 and TAK-954 0.5 mg infusion, intravenously once on Day 2.
Period 2: TAK-954 placebo-matching infusion, intravenously, once on Day 1 and Day 2.
Period 3: TAK-954 0.1 mg, infusion, intravenously, once on Day 1 and TAK-954 2 mg, infusion, intravenously, once on Day 2.
A washout period of at least 16 days was maintained between each Treatment Period.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3: TAK-954 0.5 mg + TAK-954 1 mg + Placebo</title>
          <description>Period 1: TAK-954 0.1 mg, infusion, intravenously, once on Day 1 and TAK-954 0.5 mg, infusion, intravenously once on Day 2.
Period 2: TAK-954 0.1 mg, infusion, intravenously, once on Day 1 and TAK-954 1 mg, infusion, intravenously, once on Day 2.
Period 3: TAK-954 placebo-matching infusion, intravenously, once on Day 1 and Day 2.
A washout period of at least 16 days was maintained between each Treatment Period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (at Least 16 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 (2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (at Least 16 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3 (2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety set included all participants who received at least one dose of the study drug (active or placebo).</population>
      <group_list>
        <group group_id="B1">
          <title>Sequence 1: Placebo + TAK-954 1 mg + TAK-954 2 mg</title>
          <description>Period 1: TAK-954 placebo-matching infusion, intravenously, once on Day 1 and Day 2.
Period 2: TAK-954 0.1 mg, infusion, intravenously, once on Day 1 and TAK-954 1 mg infusion, intravenously, once on Day 2.
Period 3: TAK-954 0.1 mg, infusion, intravenously, once on Day 1 and TAK-954 2 mg infusion, intravenously, once on Day 2.
A washout period of at least 16 days was maintained between each Treatment Period.</description>
        </group>
        <group group_id="B2">
          <title>Sequence 2: TAK-954 0.5 mg + Placebo + TAK-954 2 mg</title>
          <description>Period 1: TAK-954 0.1 mg, infusion, intravenously, once on Day 1 and TAK-954 0.5 mg infusion, intravenously once on Day 2.
Period 2: TAK-954 placebo-matching infusion, intravenously, once on Day 1 and Day 2.
Period 3: TAK-954 0.1 mg, infusion, intravenously, once on Day 1 and TAK-954 2 mg, infusion, intravenously, once on Day 2.
A washout period of at least 16 days was maintained between each Treatment Period.</description>
        </group>
        <group group_id="B3">
          <title>Sequence 3: TAK-954 0.5 mg + TAK-954 1 mg + Placebo</title>
          <description>Period 1: TAK-954 0.1 mg, infusion, intravenously, once on Day 1 and TAK-954 0.5 mg, infusion, intravenously once on Day 2.
Period 2: TAK-954 0.1 mg, infusion, intravenously, once on Day 1 and TAK-954 1 mg, infusion, intravenously, once on Day 2.
Period 3: TAK-954 placebo-matching infusion, intravenously, once on Day 1 and Day 2.
A washout period of at least 16 days was maintained between each Treatment Period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" spread="14.14"/>
                    <measurement group_id="B2" value="33.0" spread="4.24"/>
                    <measurement group_id="B3" value="46.5" spread="2.12"/>
                    <measurement group_id="B4" value="35.8" spread="10.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.80" spread="13.152"/>
                    <measurement group_id="B2" value="67.60" spread="9.758"/>
                    <measurement group_id="B3" value="80.55" spread="0.495"/>
                    <measurement group_id="B4" value="77.65" spread="10.858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.5" spread="7.78"/>
                    <measurement group_id="B2" value="167.0" spread="21.21"/>
                    <measurement group_id="B3" value="165.5" spread="4.95"/>
                    <measurement group_id="B4" value="167.0" spread="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.655" spread="1.9021"/>
                    <measurement group_id="B2" value="24.375" spread="2.5102"/>
                    <measurement group_id="B3" value="29.455" spread="1.7607"/>
                    <measurement group_id="B4" value="27.828" spread="3.1252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) for TAK-954</title>
        <time_frame>Dosing on Day 2 in Period 1 up to 14 days after last dose of study drug on Day 2 of Period 3 (up to Day 52)</time_frame>
        <population>The safety set included all participants who received at least one dose of the study drug (active or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) for TAK-954</title>
          <population>The safety set included all participants who received at least one dose of the study drug (active or placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Change From Baseline in Vital Signs for TAK-954</title>
        <time_frame>Dosing on Day 2 in Period 1 up to 14 days after last dose of study drug on Day 2 of Period 3 (up to Day 52)</time_frame>
        <population>The safety set included all participants who received at least one dose of the study drug (active or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change From Baseline in Vital Signs for TAK-954</title>
          <population>The safety set included all participants who received at least one dose of the study drug (active or placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG) for TAK-954</title>
        <time_frame>Dosing on Day 2 in Period 1 up to 14 days after last dose of study drug on Day 2 of Period 3 (up to Day 52)</time_frame>
        <population>The safety set included all participants who received at least one dose of the study drug (active or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG) for TAK-954</title>
          <population>The safety set included all participants who received at least one dose of the study drug (active or placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Notable Shifts From Baseline to Abnormal Post-dose in Clinical Laboratory Values for TAK-954</title>
        <time_frame>Dosing on Day 2 in Period 1 up to 14 days after last dose of study drug on Day 2 of Period 3 (up to Day 52)</time_frame>
        <population>The safety set included all participants who received at least one dose of the study drug (active or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Notable Shifts From Baseline to Abnormal Post-dose in Clinical Laboratory Values for TAK-954</title>
          <population>The safety set included all participants who received at least one dose of the study drug (active or placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954</title>
        <time_frame>Day 2 pre-dose and at multiple time points (up to 336 hours) post-dose</time_frame>
        <population>The pharmacokinetic (PK) set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954</title>
          <population>The pharmacokinetic (PK) set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
          <units>picogram*hour per milliliter (pg*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88930" spread="23.0"/>
                    <measurement group_id="O2" value="163200" spread="12.8"/>
                    <measurement group_id="O3" value="298400" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954</title>
        <time_frame>Day 2 pre-dose and at multiple time points (up to 336 hours) post-dose</time_frame>
        <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954</title>
          <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
          <units>pg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89220" spread="22.8"/>
                    <measurement group_id="O2" value="163700" spread="12.8"/>
                    <measurement group_id="O3" value="299500" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ceoi: Plasma Concentration Observed at the End of Infusion for TAK-954</title>
        <time_frame>Day 2 pre-dose and at multiple time points (up to 336 hours) post-dose</time_frame>
        <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Ceoi: Plasma Concentration Observed at the End of Infusion for TAK-954</title>
          <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7502" spread="24.1"/>
                    <measurement group_id="O2" value="15260" spread="12.9"/>
                    <measurement group_id="O3" value="30270" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL: Total Clearance After Intravenous Administration for TAK-954</title>
        <time_frame>Day 2 pre-dose and at multiple time points (up to 336 hours) post-dose</time_frame>
        <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>CL: Total Clearance After Intravenous Administration for TAK-954</title>
          <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
          <units>liter per hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.604" spread="22.8"/>
                    <measurement group_id="O2" value="6.110" spread="12.8"/>
                    <measurement group_id="O3" value="6.679" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vz: Volume of Distribution During the Terminal Disposition Phase After Intravenous Administration for TAK-954</title>
        <time_frame>Day 2 pre-dose and at multiple time points (up to 336 hours) post-dose</time_frame>
        <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz: Volume of Distribution During the Terminal Disposition Phase After Intravenous Administration for TAK-954</title>
          <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
          <units>liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.9" spread="13.7"/>
                    <measurement group_id="O2" value="387.7" spread="45.6"/>
                    <measurement group_id="O3" value="901.7" spread="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ae: Amount of Unchanged Drug Excreted in the Urine for TAK-954 on Day 2 up to 12 Hours Post-dose</title>
        <time_frame>Day 2 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
        <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae: Amount of Unchanged Drug Excreted in the Urine for TAK-954 on Day 2 up to 12 Hours Post-dose</title>
          <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
          <units>nanogram</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104300" spread="6.3"/>
                    <measurement group_id="O2" value="226000" spread="16.0"/>
                    <measurement group_id="O3" value="408900" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ae: Amount of Unchanged Drug Excreted in the Urine for TAK-954 on Day 2 up to 24 Hours Post-dose</title>
        <time_frame>Day 2 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations). PK-evaluable population where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae: Amount of Unchanged Drug Excreted in the Urine for TAK-954 on Day 2 up to 24 Hours Post-dose</title>
          <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations). PK-evaluable population where data at specified time points was available.</population>
          <units>nanogram</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53200" spread="27.3"/>
                    <measurement group_id="O2" value="115300" spread="19.9"/>
                    <measurement group_id="O3" value="190700" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ae: Amount of Unchanged Drug Excreted in the Urine for TAK-954 on Day 2 up to 36 Hours Post-dose</title>
        <time_frame>Day 2 pre-dose and at multiple time points (up to 36 hours) post-dose</time_frame>
        <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae: Amount of Unchanged Drug Excreted in the Urine for TAK-954 on Day 2 up to 36 Hours Post-dose</title>
          <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
          <units>nanogram</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32420" spread="17.3"/>
                    <measurement group_id="O2" value="66560" spread="5.3"/>
                    <measurement group_id="O3" value="103600" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fe: Fraction of TAK-954 Excreted in Urine on Day 2 up to 12 Hours Post-dose</title>
        <time_frame>Day 2 pre-dose and at multiple time points (up to 12 hours) post-dose</time_frame>
        <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations). PK-evaluable population where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Fe: Fraction of TAK-954 Excreted in Urine on Day 2 up to 12 Hours Post-dose</title>
          <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations). PK-evaluable population where data at specified time points was available.</population>
          <units>percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.86" spread="6.3"/>
                    <measurement group_id="O2" value="22.60" spread="16.0"/>
                    <measurement group_id="O3" value="20.45" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fe: Fraction of TAK-954 Excreted in Urine on Day 2 up to 24 Hours Post-dose</title>
        <time_frame>Day 2 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Fe: Fraction of TAK-954 Excreted in Urine on Day 2 up to 24 Hours Post-dose</title>
          <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
          <units>percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.64" spread="27.3"/>
                    <measurement group_id="O2" value="11.53" spread="19.9"/>
                    <measurement group_id="O3" value="9.534" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fe: Fraction of TAK-954 Excreted in Urine on Day 2 up to 36 Hours Post-dose</title>
        <time_frame>Day 2 pre-dose and at multiple time points (up to 36 hours) post-dose</time_frame>
        <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Fe: Fraction of TAK-954 Excreted in Urine on Day 2 up to 36 Hours Post-dose</title>
          <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
          <units>percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.484" spread="17.3"/>
                    <measurement group_id="O2" value="6.656" spread="5.3"/>
                    <measurement group_id="O3" value="5.181" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CLR: Renal Clearance for TAK-954</title>
        <time_frame>Day 2 pre-dose and at multiple time points (up to 36 hours) post-dose</time_frame>
        <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>CLR: Renal Clearance for TAK-954</title>
          <population>The PK set included all participants who complied sufficiently with the protocol and display an evaluable PK profile (example, exposure to treatment, availability of measurements and absence of major protocol violations).</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.457" spread="19.9"/>
                    <measurement group_id="O2" value="3.933" spread="8.9"/>
                    <measurement group_id="O3" value="3.624" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Stool of TAK-954 Within 36 Hours Post-dose on Day 2</title>
        <time_frame>Day 2 dosing and at multiple time points (up to 36 hours) post-dose</time_frame>
        <population>The pharmacodynamic (PD) set included all participants who received at least one dose of the study drug (active or placebo) and had completed at least 1 PD sampling period and/or had at least 1 evaluable parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Stool of TAK-954 Within 36 Hours Post-dose on Day 2</title>
          <population>The pharmacodynamic (PD) set included all participants who received at least one dose of the study drug (active or placebo) and had completed at least 1 PD sampling period and/or had at least 1 evaluable parameter.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Stools of TAK-954 Within 36 Hours Post-dose on Day 2</title>
        <time_frame>Day 2 dosing and at multiple time points (up to 36 hours) post-dose</time_frame>
        <population>The PD set included all participants who received at least one dose of the study drug (active or placebo) and had completed at least 1 PD sampling period and/or had at least 1 evaluable parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Stools of TAK-954 Within 36 Hours Post-dose on Day 2</title>
          <population>The PD set included all participants who received at least one dose of the study drug (active or placebo) and had completed at least 1 PD sampling period and/or had at least 1 evaluable parameter.</population>
          <units>stools</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="3.40"/>
                    <measurement group_id="O2" value="2.0" spread="0.82"/>
                    <measurement group_id="O3" value="1.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Instances of Stool Type of TAK-954 Based on Bristol Stool Form Scale</title>
        <description>Number of occurrences for each stool type was reported based on their type assessed from Bristol Stool form scale. The Bristol Stool Form Scale was used to assess the stool shape using a 7-point scale. Where, Type 1 = separate hard lumps, like nuts (hard to pass), Type 2 = sausage-shaped but lumpy, Type 3 = like a sausage but with cracks on the surface, Type 4 = like a sausage or snake, smooth and soft, Type 5 = soft blobs with clear-cut edges (passed easily), Type 6 = fluffy pieces with ragged edges, a mushy stool, Type 7 = watery, no solid pieces; entirely liquid. A score of 1 or 2 indicates constipation and a score of 6 or 7 indicates diarrhea.</description>
        <time_frame>Day 2 dosing and at multiple time points (up to 36 hours) post-dose</time_frame>
        <population>The PD set included all participants who received at least one dose of the study drug (active or placebo) and had completed at least 1 PD sampling period and/or had at least 1 evaluable parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Dose: TAK-954 0.5 mg</title>
            <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Dose: TAK-954 1 mg</title>
            <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Dose: TAK-954 2 mg</title>
            <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Instances of Stool Type of TAK-954 Based on Bristol Stool Form Scale</title>
          <description>Number of occurrences for each stool type was reported based on their type assessed from Bristol Stool form scale. The Bristol Stool Form Scale was used to assess the stool shape using a 7-point scale. Where, Type 1 = separate hard lumps, like nuts (hard to pass), Type 2 = sausage-shaped but lumpy, Type 3 = like a sausage but with cracks on the surface, Type 4 = like a sausage or snake, smooth and soft, Type 5 = soft blobs with clear-cut edges (passed easily), Type 6 = fluffy pieces with ragged edges, a mushy stool, Type 7 = watery, no solid pieces; entirely liquid. A score of 1 or 2 indicates constipation and a score of 6 or 7 indicates diarrhea.</description>
          <population>The PD set included all participants who received at least one dose of the study drug (active or placebo) and had completed at least 1 PD sampling period and/or had at least 1 evaluable parameter.</population>
          <units>number of occurrences</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Lead-in Dose: Day 1 of Period 1, 2, and 3; Treatment Dose: Dosing on Day 2 in Period 1 up to 14 days after last dose of study drug on Day 2 of Period 3 (up to Day 52)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lead-in Dose: TAK-954 0.1 mg</title>
          <description>TAK-954 0.1 mg, infusion, intravenously, once on Day 1 of Period 1, 2 or 3 in Sequence 1, 2, or 3.</description>
        </group>
        <group group_id="E2">
          <title>Lead-in Dose: Placebo</title>
          <description>TAK-954 placebo-matching, infusion, intravenously, once on Day 1 of Period 1, 2, or 3 in Sequence 1, 2, or 3.</description>
        </group>
        <group group_id="E3">
          <title>Treatment Dose: TAK-954 0.5 mg</title>
          <description>TAK-954 0.5 mg, infusion, intravenously, once on Day 2 of Period 1 in Sequence 2 or 3.</description>
        </group>
        <group group_id="E4">
          <title>Treatment Dose: TAK-954 1 mg</title>
          <description>TAK-954 1 mg, infusion, intravenously, once on Day 2 of Period 2 in Sequence 1 or 3.</description>
        </group>
        <group group_id="E5">
          <title>Treatment Dose: TAK-954 2 mg</title>
          <description>TAK-954 2 mg, infusion, intravenously, once on Day 2 of Period 3 in Sequence 1 or 2.</description>
        </group>
        <group group_id="E6">
          <title>Treatment Dose: Placebo</title>
          <description>TAK-954 placebo-matching, infusion, intravenously once on Day 2 of Period 1, 2 and 3.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

